Bharat Biotech chairman and MD Krishna Ella (right) and Serum Institute CEO Adar Poonawalla. Photos: Twitter and PTI.
For all the Narendra Modi government’s desire to push an Indian company to the forefront of the national COVID-19 response, it has actually put an Indian company in an awkward, even untenable, position.
On January 3, the Drug Controller General of India (DCGI) announced emergency-use approvals for two vaccine candidates in the country: Bharat Biotech’s Covaxin and Serum Institute’s Covishield. The event was met with backlash almost immediately, as droves of researchers hit Twitter and Facebook to interrogate and argue over the terms of the DCGI’s approval.